Another recent preclinical study showed that the combination of ibrutinib and lenalidomide is synthetic lethal in blocking IRF4 expression, increasing IFNβ production, and killing ABC-DLBCL cells in vitro and in vivo [90]. Here, IFNB1 is linked to diffuse large B-cell lymphoma.